Current medications and influencing factors for senile patients with NVAF

doi:10.19803/j.1672-8629.2022.03.15

Abstract

Abstract: Objective To investigate current medications for elderly patients with non-valvular atrial fibrillation (NVAF) and the effect on anticoagulant therapies. Methods A total of 482 elderly patients with NVAF hospitalized in cardiovascular departments of five big hospitals in Changsha between March 2015 and March 2019 were selected as the subjects. A self-designed questionnaire was used to investigate the demographic data that was compared between the two groups. The usage of antithrombotic therapies and multiple drugs (≥5 drugs) was evaluated, and the influencing factors of multiple drugs were analyzed by logistic regression analysis. Results Among the 482 patients, 250 (51.87%) were properly treated, 58 (12.05%) were over-treated, 37 (7.68%) were undertreated, and 137 (28.42%) were left untreated. Logistic regression analysis showed that levels of education, type of medical insurance, hypertension, diabetes, coronary heart disease and heart failure were independent risk factors for multiple drug use (P<0.05). Conclusion Multiple medication is common in elderly NVAF patients, and the proportion of anticoagulant therapies needs to be improved.

Key words: advanced age, non-valvular atrial fibrillation, multiple drug use, anticoagulation

CLC Number:

R969.3

CHAI Xiaoli, ZHANG Chen, FENG Qingchun, LIU Huan. Current medications and influencing factors for senile patients with NVAF[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 302-305.

References

[1] LI MM, LIU JP, LI JY, et al.Influencing factors of multiple drug use and anticoagulant therapy in elderly patients with non-valvular atrial fibrillation[J]. Chinese Medicine, 2019,14(1): 9-13.
[2] ZHAO RH.Evaluation of the efficacy and safety of new oral anticoagulant (NOACs) in elderly patients with non-valvular atrial fibrillation[D]. Shanxi Medical University(山西医科大学), 2017.
[3] KAWABATA M, GOYA M, SASAKI T, et al.Left Atrial appendage thrombi formation in japanese non-valvular atrial fibrillation patients during anticoagulation therapy-warfarin vs. direct oral anticoagulants[J]. Circ J, 2017, 81(5): 645-651.
[4] PAPPAS MA, BARNES GD, VIJAN S.Personalizing bridging anticoagulation in patients with nonvalvular atrial fibrillation-a microsimulation analysis[J]. J Gen In Med, 2017, 32(4): 464-470.
[5] ZHAO RH, LI XM, MA Y, et al.Evaluation of the efficacy and safety of new oral anticoagulants in elderly patients with non-valvular atrial fibrillation[J]. Chinese Medicine and Clinic, 2017, 17(6): 805-809.
[6] YANG XC.Interpretation of the 2016 European college of cardiology guidelines for the Management of Atrial Fibrillation[J]. Chinese Journal of Interventional Cardiology, 2016, 24(11): 623-628.
[7] MENG WC.Comparative observation on the safety of different antithrombotic drugs in elderly patients with non-valvular atrial fibrillation[J]. People's Military Doctor(人民军医), 2017, 60(7): 45-47.
[8] DELLUC A, WANG T, YAP E, et al.Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH[J]. Journal of Thrombosis and Haemostasis, 2019, 17(8) : 1247-1252.
[9] KANG SH, CHOI EK, HAN KD, et al.Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based study[J]. Circulation, 2017, 81(8): 1158-1164.
[10] HUANG J, YE YM, WANG Q, et al.Investigation on clinical characteristics and antithrombotic therapy in elderly patients with non-valvular atrial fibrillation[J]. Lingnan Journal of Cardiovascular Diseases, 2018, 24(3): 301-303, 310.
[11] PROSPERI-PORTA G, SCHNELL G, COLBERT J, et al.Multiple thrombo-embolic events from a left atrial appendage occlusion device[J]. Can J Cardiol, 2018, 34(3): 342.
[12] ZHANG W, WANG XB, WU YT, et al.A comparative study of benefits and risks of new oral anticoagulants in the treatment of elderly patients with non-valvular atrial fibrillation[J]. Chinese Journal of Evidence-based Cardiovascular Medicine, 2017, 9(9): 1096-1098.
[13] SAGA I, MIKA L, TUIJA V, et al.Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion[J]. Europace, 2018, 20(4): 565-568.
[14] CHEN L, GONG YX, ZHANG XL.A comparative study on the clinical efficacy of rivasaban and warfarin in the treatment of elderly (≥ 80 years old) patients with non-valvular atrial fibrillation[J]. Journal of practical Cardiac, Cerebrovascular and Pulmonary Vascular Diseases, 2018, 26(9): 63-66.
[15] LI J, SHI J, WU WB, et al.Effect of antithrombotic therapy on cerebrovascular accident in elderly patients with non-valvular atrial fibrillation[J]. Chinese Journal of General Practitioners, 2019, 18(2): 166-169.
[16] LI X, DEITELZWEIG S, KESHISHIAN A, et al.Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients[J]. Thrombosis & Haemostasis, 2017, 117(6): 1072-1082.
[17] LIP GYH, AL-SAADY N, JIN J, et al.Anticoagulation control in warfarin-treated patients undergoing cardioversion of atrial fibrillation (from the edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation trial)[J]. Am J Cardiol, 2017, 120(5): 792-796.
[18] LIANG CB, MA JH, LIU Y, et al.Study on the efficacy and safety of rifampicaban and dabigar in anticoagulation therapy in elderly patients with non-valvular atrial fibrillation[J]. Journal of Clinical Military Medicine, 2018, 46(5): 60-63.